JP2002533456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002533456A5 JP2002533456A5 JP2000591031A JP2000591031A JP2002533456A5 JP 2002533456 A5 JP2002533456 A5 JP 2002533456A5 JP 2000591031 A JP2000591031 A JP 2000591031A JP 2000591031 A JP2000591031 A JP 2000591031A JP 2002533456 A5 JP2002533456 A5 JP 2002533456A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound according
- animal
- need
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 48
- 150000001875 compounds Chemical class 0.000 description 31
- 238000000034 method Methods 0.000 description 14
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 208000019664 bone resorption disease Diseases 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 201000009273 Endometriosis Diseases 0.000 description 4
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 4
- 102100038595 Estrogen receptor Human genes 0.000 description 4
- 101710196141 Estrogen receptor Proteins 0.000 description 4
- 102100029951 Estrogen receptor beta Human genes 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 210000000918 epididymis Anatomy 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000003076 Osteolysis Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 239000003256 environmental substance Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000009441 vascular protection Effects 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 0 CCN(CC)CCOc(cc1)ccc1C(c(c(OC1=*)c2)ccc2O)=C1c1ccccc1 Chemical compound CCN(CC)CCOc(cc1)ccc1C(c(c(OC1=*)c2)ccc2O)=C1c1ccccc1 0.000 description 1
- KKFMLXDEDGNDHG-UHFFFAOYSA-N Oc(cc1)cc(OC2)c1C(c(cc1)ccc1OCCN1CCCCC1)=C(c(cc1)ccc1Cl)C2=O Chemical compound Oc(cc1)cc(OC2)c1C(c(cc1)ccc1OCCN1CCCCC1)=C(c(cc1)ccc1Cl)C2=O KKFMLXDEDGNDHG-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000004282 imidazolidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])N([H])C1([H])* 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11447298P | 1998-12-30 | 1998-12-30 | |
| US60/114,472 | 1998-12-30 | ||
| PCT/US1999/031290 WO2000039120A2 (en) | 1998-12-30 | 1999-12-30 | Compounds and methods for modulation of estrogen receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002533456A JP2002533456A (ja) | 2002-10-08 |
| JP2002533456A5 true JP2002533456A5 (enExample) | 2006-11-30 |
Family
ID=22355427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000591031A Pending JP2002533456A (ja) | 1998-12-30 | 1999-12-30 | エストロゲン受容体のモジュレートを行うための化合物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1140889B1 (enExample) |
| JP (1) | JP2002533456A (enExample) |
| KR (1) | KR100615757B1 (enExample) |
| CN (2) | CN1155589C (enExample) |
| AT (1) | ATE248157T1 (enExample) |
| AU (1) | AU765159B2 (enExample) |
| CA (1) | CA2356986A1 (enExample) |
| DE (1) | DE69910830T2 (enExample) |
| DK (1) | DK1140889T3 (enExample) |
| ES (1) | ES2207982T3 (enExample) |
| HK (1) | HK1041258B (enExample) |
| IL (2) | IL144003A0 (enExample) |
| PT (1) | PT1140889E (enExample) |
| WO (1) | WO2000039120A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6822563B2 (en) | 1997-09-22 | 2004-11-23 | Donnelly Corporation | Vehicle imaging system with accessory control |
| US5877897A (en) | 1993-02-26 | 1999-03-02 | Donnelly Corporation | Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array |
| US7655894B2 (en) | 1996-03-25 | 2010-02-02 | Donnelly Corporation | Vehicular image sensing system |
| US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| CA2367895A1 (en) | 1999-03-17 | 2000-09-21 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AU781282B2 (en) * | 1999-12-30 | 2005-05-12 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| EP1281710A1 (en) * | 2001-08-03 | 2003-02-05 | CHIESI FARMACEUTICI S.p.A. | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| EP1229036B1 (en) * | 2001-01-24 | 2005-01-12 | CHIESI FARMACEUTICI S.p.A. | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| SK287086B6 (sk) * | 2001-01-24 | 2009-11-05 | Chiesi Farmaceutici S.P.A. | 2H-1-Benzopyránové deriváty, farmaceutické prostriedky s ich obsahom a ich použitie |
| CN100516059C (zh) * | 2001-04-10 | 2009-07-22 | 宝生物工程株式会社 | 治疗剂 |
| US7148252B2 (en) * | 2001-10-03 | 2006-12-12 | Signal Pharmaceuticals, Llc | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| AU2003239155B2 (en) * | 2002-04-19 | 2008-12-04 | Novartis Ag | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
| EP1504276B1 (en) | 2002-05-03 | 2012-08-08 | Donnelly Corporation | Object detection system for vehicle |
| US7091235B2 (en) | 2002-10-15 | 2006-08-15 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| FR2849653B1 (fr) * | 2003-01-08 | 2006-08-25 | B F B Etudes Et Rech S Experim | Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant |
| WO2005028472A1 (en) * | 2003-09-15 | 2005-03-31 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
| US7526103B2 (en) | 2004-04-15 | 2009-04-28 | Donnelly Corporation | Imaging system for vehicle |
| CN101146798A (zh) * | 2005-01-21 | 2008-03-19 | 詹森药业有限公司 | 用作雌激素受体调节剂的新的杂环苯并[c]色烯衍生物 |
| AU2006262190A1 (en) * | 2005-06-24 | 2007-01-04 | Signal Pharmaceuticals, Llc. | Benzopyranone compounds for treating cancer |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| EP1860104A1 (en) * | 2006-05-22 | 2007-11-28 | Aptanomics | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof |
| CN101200460B (zh) * | 2007-11-19 | 2010-06-16 | 北京珅奥基医药科技有限公司 | 二氢苯并吡喃酮类化合物及其用途 |
| CN105541810B (zh) * | 2016-03-04 | 2019-05-17 | 南京工业大学 | 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用 |
| CN105801543B (zh) * | 2016-04-18 | 2019-08-02 | 中国药科大学 | 4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| CN105801544A (zh) * | 2016-04-18 | 2016-07-27 | 中国药科大学 | 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| CN112426420B (zh) * | 2020-12-01 | 2021-12-28 | 浙江大学 | 香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用 |
| CN112645922B (zh) * | 2020-12-24 | 2022-01-07 | 中国人民解放军空军军医大学 | 香豆素类化合物、制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2857401A (en) * | 1956-12-20 | 1958-10-21 | Searle & Co | Acetylated coumarin derivatives |
| DE4323409A1 (de) * | 1993-07-13 | 1995-01-19 | Boehringer Mannheim Gmbh | Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel |
| YU6996A (sh) * | 1995-02-06 | 1999-03-04 | Eli Lilly And Company | Upotreba benzotiofena za dobijanje leka |
| CA2270113A1 (en) * | 1996-10-28 | 1998-05-07 | Poul Jacobsen | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| ES2188909T3 (es) * | 1996-10-28 | 2003-07-01 | Novo Nordisk As | Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os |
| ZA979644B (en) * | 1996-10-28 | 1998-04-28 | Novo Nordisk As | Heterocyclic compounds, compositions and uses. |
| EP0937059A1 (en) * | 1996-10-28 | 1999-08-25 | Novo Nordisk A/S | NOVEL $i(TRANS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES |
| JP2001502708A (ja) * | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関連の疾患または症候群の予防または治療に有用な新規なシス―３，４―クロマン誘導体 |
| WO1998018771A1 (en) * | 1996-10-28 | 1998-05-07 | Novo Nordisk A/S | Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
-
1999
- 1999-12-30 AT AT99968578T patent/ATE248157T1/de not_active IP Right Cessation
- 1999-12-30 DK DK99968578T patent/DK1140889T3/da active
- 1999-12-30 ES ES99968578T patent/ES2207982T3/es not_active Expired - Lifetime
- 1999-12-30 CA CA002356986A patent/CA2356986A1/en not_active Abandoned
- 1999-12-30 PT PT99968578T patent/PT1140889E/pt unknown
- 1999-12-30 HK HK02101413.5A patent/HK1041258B/en not_active IP Right Cessation
- 1999-12-30 DE DE69910830T patent/DE69910830T2/de not_active Expired - Fee Related
- 1999-12-30 CN CNB998163740A patent/CN1155589C/zh not_active Expired - Fee Related
- 1999-12-30 EP EP99968578A patent/EP1140889B1/en not_active Expired - Lifetime
- 1999-12-30 WO PCT/US1999/031290 patent/WO2000039120A2/en not_active Ceased
- 1999-12-30 AU AU25970/00A patent/AU765159B2/en not_active Ceased
- 1999-12-30 CN CNB2004100422993A patent/CN100339374C/zh not_active Expired - Fee Related
- 1999-12-30 JP JP2000591031A patent/JP2002533456A/ja active Pending
- 1999-12-30 IL IL14400399A patent/IL144003A0/xx active IP Right Grant
- 1999-12-30 KR KR1020017008410A patent/KR100615757B1/ko not_active Expired - Fee Related
-
2001
- 2001-06-26 IL IL144003A patent/IL144003A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002533456A5 (enExample) | ||
| JP2003519219A5 (enExample) | ||
| WO2001049673A2 (en) | Compounds and methods for modulation of estrogen receptors | |
| ES2277273T3 (es) | Derivados de oxima de aril-carbaldehido, y su utilizacion como agentes estrogenicos. | |
| US7335678B2 (en) | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | |
| ES2207982T3 (es) | Compuestos y metodos para la modulacion de receptores estrogenicos. | |
| US6331562B1 (en) | Compounds and methods for modulation of estrogen receptors | |
| US6291456B1 (en) | Compounds and methods for modulation of estrogen receptors | |
| JP2001508799A (ja) | 新規カンナビノイド受容体モジュレータ | |
| WO2003070247A1 (en) | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor | |
| JPH09505830A (ja) | 炎症の治療のための１，３，５−トリ置換ピラゾール化合物 | |
| JP2007501246A (ja) | バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物 | |
| WO2002012189A1 (en) | Fused bicyclic amide compounds and medicinal use thereof | |
| JP2019513795A5 (enExample) | ||
| Habeeb et al. | Design and syntheses of diarylisoxazoles: Novel inhibitors of cyclooxygenase‐2 (COX‐2) with analgesic‐antiinflammatory activity | |
| US20060074128A1 (en) | Substituted 2-phenyl benzofurans as estrogenic agents | |
| US20050113576A1 (en) | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | |
| ZA200203942B (en) | Isoxazolecarboxamide derivatives. | |
| US20210188837A1 (en) | Nitrogen-containing 6-membered cyclic compound | |
| JP2004525184A5 (enExample) | ||
| JP2006504629A5 (enExample) | ||
| US5760040A (en) | Indole derivative for treating overproduction of dihydrotestosterone | |
| EP0721949A1 (en) | Indoline compound and 5-ht 3? receptor antagonist containing the same as active ingredient | |
| WO2005044130A9 (en) | Pdk-1/akt signaling inhibitors | |
| JP2016138053A (ja) | アロマターゼ阻害剤及びこれを含む医薬 |